Proteasome inhibitor bortezomib is a novel therapeutic agent for focal radiation-induced osteoporosis

The effects of proteasome inhibitors on bone remodeling in multiple myeloma

(2016) Maurizio Zangari et al.   BONE

Risk of second cancers in the era of modern radiation therapy: does the risk/benefit analysis overcome theoretical models?

(2016) Cyrus Chargari et al.   CANCER AND METASTASIS REVIEWS

Suppression of Sclerostin Alleviates Radiation-Induced Bone Loss by Protecting Bone-Forming Cells and Their Progenitors Through Distinct Mechanisms

(2016) Abhishek Chandra et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Carcinogenicity risk assessment of romosozumab: A review of scientific weight-of-evidence and findings in a rat lifetime pharmacology study

(2016) Luc Chouinard et al.   REGULATORY TOXICOLOGY AND PHARMACOLOGY

PTH1–34 alleviates radiotherapy-induced local bone loss by improving osteoblast and osteocyte survival

(2014) Abhishek Chandra et al.   BONE

Overview of Proteasome Inhibitor-Based Anti-cancer Therapies: Perspective on Bortezomib and Second Generation Proteasome Inhibitors versus Future Generation Inhibitors of Ubiquitin-Proteasome System

(2014) Q. Dou et al.   CURRENT CANCER DRUG TARGETS

One ring to bring them all—The role of Ku in mammalian non-homologous end joining

(2014) Gabrielle J. Grundy et al.   DNA REPAIR

PTH1–34 Blocks Radiation-induced Osteoblast Apoptosis by Enhancing DNA Repair through Canonical Wnt Pathway

(2014) Abhishek Chandra et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Beyond DNA Repair: DNA-PK Function in Cancer

(2014) J. F. Goodwin et al.   Cancer Discovery

PTH prevents the adverse effects of focal radiation on bone architecture in young rats

(2013) Abhishek Chandra et al.   BONE

Epidermal Growth Factor Receptor (EGFR) Signaling Promotes Proliferation and Survival in Osteoprogenitors by Increasing Early Growth Response 2 (EGR2) Expression

(2013) Abhishek Chandra et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Ionizing-radiation induced DNA double-strand breaks: A direct and indirect lighting up

(2013) Julien Vignard et al.   RADIOTHERAPY AND ONCOLOGY

Valosin-containing protein regulates the proteasome-mediated degradation of DNA-PKcs in glioma cells

(2013) N Jiang et al.   Cell Death & Disease

Impact of bortezomib on bone health in myeloma: A review of current evidence

(2012) Maurizio Zangari et al.   CANCER TREATMENT REVIEWS

The ubiquitin proteasome system and efficacy of proteasome inhibitors in diseases

(2012) Selvarajan Chitra et al.   International Journal of Rheumatic Diseases

Safety of osteoanabolic therapy: A decade of experience

(2012) Cristiana Capriani et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Standardized nomenclature, symbols, and units for bone histomorphometry: A 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee

(2012) David W Dempster et al.   JOURNAL OF BONE AND MINERAL RESEARCH

The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects

(2012) M A Hurchla et al.   LEUKEMIA

Bone remodelling at a glance

(2011) J. C. Crockett et al.   JOURNAL OF CELL SCIENCE

Irradiation induces bone injury by damaging bone marrow microenvironment for stem cells

(2011) X. Cao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Regulation of the 26S Proteasome Complex During Oxidative Stress

(2010) X. Wang et al.   Science Signaling

Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline

(2009) Paul G. Richardson et al.   BRITISH JOURNAL OF HAEMATOLOGY

Proteasomes Can Degrade a Significant Proportion of Cellular Proteins Independent of Ubiquitination

(2009) James M. Baugh et al.   JOURNAL OF MOLECULAR BIOLOGY